Details of the Drug
General Information of Drug (ID: DMRTHW1)
| Drug Name |
PHENYLSULFAMIDE
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
phenylsulfamide; N-phenylsulfamide; 15959-53-2; N-phenylaminosulfonamide; aniline sulfonic acid amide; CHEMBL168514; Sulfamide, phenyl-; Sulfamide, N-phenyl-; (Sulfamoylamino)Benzene; N-Phenylsulfuric diamide; SCHEMBL253104; CTK0E6878; DTXSID50574504; DEVUYWTZRXOMSI-UHFFFAOYSA-N; MolPort-030-912-022; ZINC13488090; BDBM50124170; AKOS029900887; 79499-EP2305698A2; 79499-EP2305697A2; 79499-EP2305695A2; 79499-EP2305696A2
|
||||||||||||||||||
| Indication |
|
||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 172.21 | |||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 0.4 | ||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 2 | ||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 4 | ||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||
| Drug-Molecule Activity Atlas (DMA)NEW | Click to Jump to the Detailed DMA Information of This Drug | ||||||||||||||||||
| Drug ADMET Endpoint Profile (DAE)NEW | Click to Jump to the Detailed DAE Information of This Drug | ||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||
|
||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||


